IBDEI275 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,36876,1,3,0)
 ;;=3^Squamous cell carcinoma of skin of right ear/external auric canal
 ;;^UTILITY(U,$J,358.3,36876,1,4,0)
 ;;=4^C44.222
 ;;^UTILITY(U,$J,358.3,36876,2)
 ;;=^5001035
 ;;^UTILITY(U,$J,358.3,36877,0)
 ;;=C44.229^^169^1861^34
 ;;^UTILITY(U,$J,358.3,36877,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36877,1,3,0)
 ;;=3^Squamous cell carcinoma of skin of left ear/external auric canal
 ;;^UTILITY(U,$J,358.3,36877,1,4,0)
 ;;=4^C44.229
 ;;^UTILITY(U,$J,358.3,36877,2)
 ;;=^5001036
 ;;^UTILITY(U,$J,358.3,36878,0)
 ;;=C44.212^^169^1861^9
 ;;^UTILITY(U,$J,358.3,36878,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36878,1,3,0)
 ;;=3^Basal cell carcinoma of skin of right ear/external auric canal
 ;;^UTILITY(U,$J,358.3,36878,1,4,0)
 ;;=4^C44.212
 ;;^UTILITY(U,$J,358.3,36878,2)
 ;;=^5001032
 ;;^UTILITY(U,$J,358.3,36879,0)
 ;;=C44.219^^169^1861^3
 ;;^UTILITY(U,$J,358.3,36879,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36879,1,3,0)
 ;;=3^Basal cell carcinoma of skin of left ear/external auric canal
 ;;^UTILITY(U,$J,358.3,36879,1,4,0)
 ;;=4^C44.219
 ;;^UTILITY(U,$J,358.3,36879,2)
 ;;=^5001033
 ;;^UTILITY(U,$J,358.3,36880,0)
 ;;=C92.40^^169^1862^21
 ;;^UTILITY(U,$J,358.3,36880,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36880,1,3,0)
 ;;=3^Acute promyelocytic leukemia, not having achieved remission
 ;;^UTILITY(U,$J,358.3,36880,1,4,0)
 ;;=4^C92.40
 ;;^UTILITY(U,$J,358.3,36880,2)
 ;;=^5001801
 ;;^UTILITY(U,$J,358.3,36881,0)
 ;;=C92.50^^169^1862^18
 ;;^UTILITY(U,$J,358.3,36881,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36881,1,3,0)
 ;;=3^Acute myelomonocytic leukemia, not having achieved remission
 ;;^UTILITY(U,$J,358.3,36881,1,4,0)
 ;;=4^C92.50
 ;;^UTILITY(U,$J,358.3,36881,2)
 ;;=^5001804
 ;;^UTILITY(U,$J,358.3,36882,0)
 ;;=C92.00^^169^1862^15
 ;;^UTILITY(U,$J,358.3,36882,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36882,1,3,0)
 ;;=3^Acute myeloblastic leukemia, not having achieved remission
 ;;^UTILITY(U,$J,358.3,36882,1,4,0)
 ;;=4^C92.00
 ;;^UTILITY(U,$J,358.3,36882,2)
 ;;=^5001789
 ;;^UTILITY(U,$J,358.3,36883,0)
 ;;=C92.51^^169^1862^17
 ;;^UTILITY(U,$J,358.3,36883,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36883,1,3,0)
 ;;=3^Acute myelomonocytic leukemia, in remission
 ;;^UTILITY(U,$J,358.3,36883,1,4,0)
 ;;=4^C92.51
 ;;^UTILITY(U,$J,358.3,36883,2)
 ;;=^5001805
 ;;^UTILITY(U,$J,358.3,36884,0)
 ;;=C92.41^^169^1862^20
 ;;^UTILITY(U,$J,358.3,36884,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36884,1,3,0)
 ;;=3^Acute promyelocytic leukemia, in remission
 ;;^UTILITY(U,$J,358.3,36884,1,4,0)
 ;;=4^C92.41
 ;;^UTILITY(U,$J,358.3,36884,2)
 ;;=^5001802
 ;;^UTILITY(U,$J,358.3,36885,0)
 ;;=C92.01^^169^1862^14
 ;;^UTILITY(U,$J,358.3,36885,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36885,1,3,0)
 ;;=3^Acute myeloblastic leukemia, in remission
 ;;^UTILITY(U,$J,358.3,36885,1,4,0)
 ;;=4^C92.01
 ;;^UTILITY(U,$J,358.3,36885,2)
 ;;=^5001790
 ;;^UTILITY(U,$J,358.3,36886,0)
 ;;=C92.02^^169^1862^13
 ;;^UTILITY(U,$J,358.3,36886,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36886,1,3,0)
 ;;=3^Acute myeloblastic leukemia, in relapse
 ;;^UTILITY(U,$J,358.3,36886,1,4,0)
 ;;=4^C92.02
 ;;^UTILITY(U,$J,358.3,36886,2)
 ;;=^5001791
 ;;^UTILITY(U,$J,358.3,36887,0)
 ;;=C92.42^^169^1862^19
 ;;^UTILITY(U,$J,358.3,36887,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36887,1,3,0)
 ;;=3^Acute promyelocytic leukemia, in relapse
 ;;^UTILITY(U,$J,358.3,36887,1,4,0)
 ;;=4^C92.42
 ;;^UTILITY(U,$J,358.3,36887,2)
 ;;=^5001803
 ;;^UTILITY(U,$J,358.3,36888,0)
 ;;=C92.52^^169^1862^16
 ;;^UTILITY(U,$J,358.3,36888,1,0)
 ;;=^358.31IA^4^2
